AAAAAA
Results:
1-17
|
Results: 17
Authors:
Hauns, B
Haring, B
Kohler, S
Mross, K
Unger, C
Citation: B. Hauns et al., Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer, PHYTOTHER R, 15(1), 2001, pp. 34-38
Authors:
Gunsilius, E
Gierlich, T
Mross, K
Gastl, G
Unger, C
Citation: E. Gunsilius et al., Palliative chemotherapy in pretreated patients with advanced cancer: Oral trofosfamide is effective in ovarian carcinoma, CANCER INV, 19(8), 2001, pp. 808-811
Authors:
Mross, K
Marz, W
Citation: K. Mross et W. Marz, Clinical trials: Prerequisite of evidence-based oncology. Reality, perspectives and a new tool recruited - the Internet, ONKOLOGIE, 24, 2001, pp. 24-34
Authors:
Mross, K
Citation: K. Mross, The effect of an adjuvant mistle toe treatment program in resected head and neck cancer patients: A randomized clinical trial, STRAH ONKOL, 177(9), 2001, pp. 495-496
Authors:
Mross, K
Citation: K. Mross, Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials, DRUG RESIST, 3(4), 2000, pp. 223-235
Authors:
van Zuylen, L
Gianni, L
Verweij, J
Mross, K
Brouwer, E
Loos, WJ
Sparreboom, A
Citation: L. Van Zuylen et al., Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients, ANTI-CANC D, 11(5), 2000, pp. 331-337
Authors:
Mross, K
Hollander, N
Schumacher, M
Maier-Lenz, H
Citation: K. Mross et al., The pharmacokinetics and -dynamics of paclitaxel and their relationship tothe infusion time, INT J CL PH, 38(3), 2000, pp. 145-146
Authors:
Mross, K
Robben-Bathe, P
Edler, L
Baumgart, J
Berdel, WE
Fiebig, H
Unger, C
Citation: K. Mross et al., Phase I clinical trial of a day-1,-3,-5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer - A study of the phase I study group of the Association for Medical Oncology (AIO) of the German Cancer Society, ONKOLOGIE, 23(6), 2000, pp. 576-579
Authors:
Kroger, N
Kleeberg, UR
Mross, K
Edler, L
Sass, G
Hossfeld, DK
Citation: N. Kroger et al., Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer, ONKOLOGIE, 23(1), 2000, pp. 60-62
Authors:
Mross, K
Hollander, N
Hauns, B
Schumacher, M
Maier-Lenz, H
Citation: K. Mross et al., The pharmacokinetics of a 1-h paclitaxel infusion, CANC CHEMOT, 45(6), 2000, pp. 463-470
Authors:
Mross, K
Scheulen, ME
Manegold, C
Westerhausen, M
Edler, L
Becher, R
Citation: K. Mross et al., Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma - A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society, ONKOLOGIE, 22(5), 1999, pp. 412-415
Authors:
Drevs, J
Droll, A
Mross, K
Unger, C
Citation: J. Drevs et al., Angiogenesis inhibition: Drugs in clinical trials, ONKOLOGIE, 22(4), 1999, pp. 282-290
Authors:
Fuxius, S
Unger, C
Mross, K
Citation: S. Fuxius et al., Pulmonary toxicity resulting from treatment with gemcitabine, ONKOLOGIE, 22(2), 1999, pp. 146-149
Authors:
Mross, K
Kroger, N
Herbst, K
Gastl, G
Hossfeld, D
Citation: K. Mross et al., Alteration in epirubicin pharmacokinetics and metabolism by dexverapamil: Results from a phase II study in patients with metastatic breast cancer, ONKOLOGIE, 22(1), 1999, pp. 35-40
Authors:
Kollmannsberger, C
Mross, K
Jakob, A
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience, ONCOL-BASEL, 56(1), 1999, pp. 1-12
Authors:
Hauns, B
Haring, B
Kohler, S
Mross, K
Robben-Bathe, P
Unger, C
Citation: B. Hauns et al., Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC)in patients with pancreatic cancer, ARZNEI-FOR, 49(12), 1999, pp. 1030-1034
Authors:
Mross, K
Berdel, WE
Fiebig, HH
Velagapudi, R
von Broen, IM
Unger, C
Citation: K. Mross et al., Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer, ANN ONCOL, 9(12), 1998, pp. 1323-1330
Risultati:
1-17
|